Rejected at 6:12 p.m. Apr, 08, 2024 ] by herstein.jacob
Author: Cameron
Related Note: 1509141053939
Rationale for change

QID is specific to myelosuppresion w/ hydroxyurea use, which is already tagged here

Rejection reason

Not sure why you want to delete? Tag seems appropriate to me when checking QID vs. card content

Text
Extra
Empty field
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Empty field
Bootcamp
OME
Additional Resources
Empty field
One by one
Empty field
Changed Tags
#AK_Step1_v12::#UWorld::19689
#AK_Step2_v12::#SketchyIM::07_Rheumatology::Retired_Lessons::02_Systemic_Rheumatic_Diseases::01_Rheumatoid_Arthritis_SOAP_[OLD_VERSION] #AK_Step1_v12::#Pixorize::03_Pharmacology::12_Oncology_Pharm::24_Hydroxyurea #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::12_Antimetabolites #AK_Step1_v12::#Bootcamp::Pathology::02_Cellular_Injury_&_Neoplasia::10_Cell_Cycle_Dependent_Drug_Targets #AK_Step1_v12::#Pixorize::^Missing_image #AK_Step1_v12::#SketchyPharm::08_Antineoplastics::01_Antimetabolites::01_Methotrexate,_Leucovorin,_5-fluorouracil,_Hydroxyurea #AK_Step1_v12::#B&B::14_Infectious_Disease::03_Antibiotics::03_Sulfonamides::Extra #AK_Step1_v12::#UWorld::Step::19689 #AK_Step1_v12::#B&B::12_Hematology::04_Cancer_Drugs::01_Antimetabolites #AK_Other::#AK_Original_Decks::Step_1::Lolnotacop::Drugs #AK_Step2_v12::#UWorld::COMLEX::100581 #AK_Step1_v12::#OME_banner #AK_Step1_v12::#UWorld::Step::1847 #AK_Step1_v12::#UWorld::COMLEX::27183 #AK_Step1_v12::#AMBOSS::hw0ciR #AK_Step1_v12::#B&B::13_Immunology::03_Pharm::02_Immunosuppressive_Drugs::Extra #AK_Step1_v12::#Low/HighYield::3-HighYield-temporary #AK_Step1_v12::#B&B::04_Biochem::01_Molecular::03_Pyrimidine_Metabolism #AK_Step1_v12::#AMBOSS::M4aMPk #AK_Step1_v12::#UWorld::COMLEX::24956 #AK_Step2_v12::#UWorld::Step::3786 #AK_Other::Only_Step_1 #AK_Step2_v12::#B&B::08_Infectious_Disease::01_Antibiotics::04_Other_Antibiotics::Extra #AK_Step1_v12::#AMBOSS::Cpaq7l #AK_Step2_v12::#AMBOSS::RF0l33 #AK_Step1_v12::#Bootcamp::Genetics::01_DNA_Structure::05_Clinical_Applications_of_the_Pyrimidine_Pathway #AK_Step1_v12::#AMBOSS::3UaS1P